Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Interest Coverage: 0 (At Loss) (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage?

Sichuan Kelun-Biotech Biopharmaceutical Co HKSE:06990 -2.79% 44 Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus rates HKSE:06990 with a GF Score™ of 44/100 and a GF Value™ of HK$254.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 379 Biotechnology companies, Sichuan Kelun-Biotech Biopharmaceutical Co ranks worse than 263851.98% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Sichuan Kelun-Biotech Biopharmaceutical Co's Operating Income for the six months ended in Jun. 2026 was HK$-581 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Expense for the six months ended in Jun. 2026 was HK$-2 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage or its related term are showing as below:


HKSE:06990's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 92.44
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage Related Terms

Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 0.00 0.00 0.00 0.00

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only 146.89 0.00 0.00 0.00 0.00

HKSE:06990 vs VRTX, REGN, RVMD: Interest Coverage Comparison

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage falls into.


HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Expense was HK$-7 Mil. Its Operating Income was HK$-515 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$49 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co did not have earnings to cover the interest expense.

Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

Here, for the six months ended in Jun. 2026, Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Expense was HK$-2 Mil. Its Operating Income was HK$-581 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$55 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Interest Coverage of 0 (At Loss) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #999999 out of 379 companies in the Biotechnology industry.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #999999 out of 379 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #999999 out of 379 companies for Interest Coverage. This places Sichuan Kelun-Biotech Biopharmaceutical Co in the lower half of its industry. The industry median Interest Coverage is 92.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 92.44, based on 379 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 92.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Kelun-Biotech Biopharmaceutical Co's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Interest Coverage is 0 (At Loss) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Interest Coverage: 0 (At Loss)
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value